№ files_lp_4_process_3_105207
File format: docx
Character count: 31975
File size: 45 KB
Year:
2018
Region / City:
Online / Reddit
Theme:
Psychological horror, mental health
Document Type:
Personal narrative / Reddit post
Author:
Anonymous therapist
Target Audience:
General readers of horror and psychological stories
Period Covered:
Multi-year patient case
Date Posted:
January 2019
Source URL:
https://www.reddit.com/r/nosleep/comments/a720dj/im_a_therapist_and_my_patient_has_severe_ocd/
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Note:
Year
Year:
2021
Note:
Region / City
Topic:
Obsessive-Compulsive Disorder, Pediatric OCD, Exposure and Response Prevention
Document Type:
Registration Form
Target Audience:
Mental health professionals, therapists, clinicians
Payment Amount:
$1500.00 (4-day workshop), $400.00 (1-day pediatric workshop)
Credit Card Information Required:
Yes
Registration Submission:
Email submission
Year:
2019
Source:
Reddit
Subreddit:
r/nosleep
Type of document:
Personal narrative / Fictional account
Author:
Reddit user im-a-therapist-and-my-patient-has-severe-ocd
Genre:
Horror / Psychological
Setting:
Therapist’s office, patient’s home
Content warning:
Violence, mental health issues, obsessive-compulsive disorder
Publication date:
January 23, 2019
Link:
https://www.reddit.com/r/nosleep/comments/a6805c/im_a_therapist_and_my_patient_has_severe_ocd/
Year:
2021
Region / City:
United States
Topic:
Psychological trauma, OCD, therapy, brainwashing
Document Type:
Narrative
Organization / Institution:
Not specified
Author:
Not specified
Target Audience:
General audience, readers interested in psychological horror or therapy
Period of Action:
Ongoing
Approval Date:
Not specified
Date of Changes:
Not specified
Note:
Contextual description
Year:
12
Subject:
Psychology
Topic:
Obsessive-Compulsive Disorder
Type of document:
Assessment for Learning (AFL)
Level:
Secondary education
Format:
Online resource
Source:
UAIIWUO Exampro
Link:
https://UAIIWUO.exampro.net
Note:
Year
Subject:
Immigration and Refugee Status Verification
Document Type:
Guide
Document Type:
Clinical Guidelines
Authors:
Dr Bethan McMinn Consultant Community Paediatrician; Dr Klara Brzyska Paediatric ST4
Approval / Effective Date:
01/01/2023
Review Date:
01/01/2025
Version:
1
Target Audience:
People who need to know about this document in detail
Note:
Paediatricians (acute and community)
Disclaimer:
If the review date of this document has passed, please ensure that the version you are using is the most up to date version either by contacting the author.
Year:
2023
Region / City:
East Anglia, Wales
Theme:
Early Developmental Impairment, Intellectual Disability, Paediatric Assessment
Institution:
Cwm Taf Morgannwg University Health Board
Author:
Dr Bethan McMinn, Dr Klara Brzyska
Period of validity:
01/01/2023 - 01/01/2025
Approval Date:
01/01/2023
Year:
1998–2004
Region / City:
Baltimore, New York
Topic:
Communication, Special Education, Disability Support
Document Type:
Educational Guide / Reference
Institution / Organization:
Paul H. Brookes Publishing Co., Charles E. Merrill
Authors:
Downing, J.E.; Beukelman, D.R.; Mirenda, P.; Orelove, F.P.; Sobsey, D.; Snell, M.E.; Brown, F.
Target Audience:
Educators, Special Education Professionals
Period Covered:
Late 20th – early 21st century
Communication Types:
Receptive, Expressive, Symbolic, Nonsymbolic
Instructional Focus:
Strength-based approaches, observation skills, augmentative and alternative communication methods
Reference Systems:
Picture symbols, sign language, Braille, verbal speech, object cues, gestures, switch activation
Year:
2021
Region / City:
United Kingdom
Subject:
Health economics, antimicrobial evaluation
Document type:
Final report
Organization / Institution:
Centre for Health Economics, University of York; Health Economics and Decision Science, University of Sheffield
Author:
Sue Harnan, Ben Kearns, Alison Scope, Laetitia Schmitt, Dina Jankovic, Jean Hamilton, Ruth Wong, Tushar Srivastava, Harry Hill, Chu Chang Ku, Kate Ren, Claire Rothery, Laura Bojke, Mark Sculpher, Beth Woods
Target audience:
Healthcare professionals, policymakers, researchers
Period of validity:
2016 - ongoing
Approval date:
October 2021
Date of last modification:
October 2021
Year:
Not specified
Region / City:
North Northamptonshire
Topic:
Mental Health, Severe Mental Illness, Social Care
Document Type:
Request for Quotation (RFQ)
Organization / Institution:
North Northamptonshire Council
Author:
Not specified
Target Audience:
Potential suppliers
Effective Period:
Not specified
Approval Date:
Not specified
Date of Amendments:
Not specified
Canberra Health Services Guideline Apixaban and Rivaroxaban Use in Adults with Severe Kidney Disease
Year:
2021
Region / City:
Canberra, Australia
Topic:
Pharmacology / Kidney Disease
Document Type:
Clinical Guideline
Institution:
Canberra Health Services
Author:
Not specified
Target Audience:
Medical staff and pharmacists
Period of Validity:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Year:
2017–2021
Medical field:
Sleep medicine
Condition:
Moderate to severe obstructive sleep apnea
Intervention:
Hypoglossal nerve stimulation
Procedure codes:
64582, 64583, 64584
Type of document:
Evidence review and policy summary
Reviewing bodies:
NICE; VbBS; HERC
Last review date:
November 2021
Study types included:
Systematic review; randomized controlled trial; prospective and retrospective case series
Number of studies:
7
Total patients:
326
Geographic context:
United Kingdom; United States
Regulatory context:
Clinical governance and payer policy assessment
Year:
2022
Region / City:
Australia
Subject:
Pharmacology, Pharmaceutical Benefits Scheme (PBS)
Document Type:
Submission
Organization / Institution:
Sanofi-Aventis Australia Pty Ltd
Author:
Not specified
Target Audience:
Medical practitioners, healthcare professionals
Period of validity:
Not specified
Approval Date:
3 June 2022
Date of Changes:
Not specified
Contextual Description:
A regulatory submission detailing the request for listing of dupilumab in new forms for treating severe atopic dermatitis and uncontrolled severe asthma in pediatric patients under the PBS.
Year:
2025
Region / City:
UK
Topic:
Healthcare, Medication Guidelines
Document Type:
Medical Protocol
Organisation:
National Ambulance Service Medical Directors (NASMeD)
Author:
Dr. Elizabeth Miller, Dr. Dave Macklin, Mr. Andy Curran, Rosie England, Cathryn James, Dan Haworth, Tracy Rogers, Jo Jenkins, Rosie Furner
Target Audience:
Registered healthcare professionals, Paramedics, Nurses, Midwives
Effective Date:
May 2023
Review Date:
October 2025
Expiry Date:
April 2026
Approval Date:
May 2025
Change History:
Includes updates to drug administration protocols and clinical guidelines
Year:
2023
Region / City:
Australia
Topic:
Hidradenitis Suppurativa Treatment
Document Type:
Submission for Pharmaceutical Benefits Scheme (PBS) Listing
Organ / Institution:
Novartis Pharmaceuticals Australia Pty Limited
Author:
Novartis Pharmaceuticals Australia Pty Limited
Target Audience:
Medical professionals, Healthcare policymakers
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Amendments:
Not specified
Category / Program:
General Schedule (Code GE)
Prescriber Type:
Dental Medical Practitioners, Nurse Practitioners, Optometrists, Midwives
Restriction Type:
Authority Required
Severity:
Moderate to severe
Condition:
Hidradenitis suppurativa
Treatment Phase:
Initial treatment
Clinical Criteria:
Hurley stage II or III grading, abscess and inflammatory nodule count ≥ 3, failure to respond to antibiotics
Treatment Criteria:
Dermatologist supervision
Population Criteria:
Adult patients
Administrative Advice:
Subcutaneous injection
Prescribing Instructions:
Must assess disease severity, first 4 weeks under restriction
Cost:
$6,145.10 for 300 mg/2 mL pre-filled syringe/pen
Source:
Table 1.1, p25; Table 1.6, p35; Table 1.7, pp36-37; Table 1.7, p38
Year:
2019
Region / City:
United Kingdom
Topic:
Chronic Obstructive Pulmonary Disease (COPD), Oxygen Saturation
Document Type:
Guidance
Organization:
National Institute for Health and Care Excellence (NICE)
Author:
NICE
Target Audience:
General practitioners, healthcare professionals
Period of Validity:
Not specified
Approval Date:
August 2019
Date of Last Update:
N/A
Year:
2022-2023
Region / City:
Florida
Topic:
Education, Special Education, Accessibility
Document Type:
Official guideline
Organization:
Florida Department of Education (FLDOE)
Author:
Not specified
Target Audience:
Case managers, educators, IEP team members
Period of validity:
Ongoing, annual requests
Approval Date:
Not specified
Date of changes:
Not specified
Year:
2022
Region / City:
York
Theme:
Special Education, Curriculum Design
Document Type:
Educational Policy
Organization / Institution:
Applefields School
Author:
Applefields School Leadership Team
Target Audience:
Educators, Special Education Professionals, Parents of Students with Severe Learning Difficulties
Period of Validity:
Ongoing
Approval Date:
2022
Modification Date:
Ongoing
Year:
2017
Region / City:
Emergency Department
Topic:
Severe Sepsis, Septic Shock, Patient Rescreening
Document Type:
Advisory, Medical Alert
Institution:
UCLA
Author:
Not specified
Target Audience:
Emergency Department Nurses
Action Period:
3/3/17 – proposed changes
Approval Date:
Not specified
Modification Date:
3/24/17
Context:
A guideline for the early identification and rescreening of patients at risk for severe sepsis or septic shock in an emergency department setting, with detailed criteria for triggers and actions.
Drug name:
Apremilast
Brand name:
Otezla
Dosage form:
Tablet
Strength:
30 mg
Pack composition:
4 tablets of 10 mg, 4 tablets of 20 mg, 19 tablets of 30 mg
Sponsor:
Amgen Australia Pty Ltd
Regulatory status:
TGA registered
TGA registration date:
19 March 2015
Indication:
Severe plaque psoriasis
Previous indication:
Psoriatic arthritis and moderate to severe plaque psoriasis
Application type:
Minor resubmission
Requested listing:
PBS General Schedule, Authority Required (STREAMLINED)
Comparator:
Cyclosporin
Clinical population:
Patients with severe plaque psoriasis intolerant of or contraindicated to methotrexate
Primary outcome:
PASI-75 at 16 weeks
Clinical claim:
Non-inferior comparative efficacy and safety versus cyclosporin
Regulatory body:
Pharmaceutical Benefits Advisory Committee
Submission history period:
2015–2018
Geographic scope:
Australia
Source type:
Public summary document excerpt